Published in Spinal Cord on June 01, 2010
Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury. Neurotherapeutics (2011) 1.16
Effects of gabapentin on muscle spasticity and both induced as well as spontaneous autonomic dysreflexia after complete spinal cord injury. Front Physiol (2012) 0.90
Cardiovascular dysfunction following spinal cord injury. Neural Regen Res (2016) 0.88
Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditions. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Cardiovascular Dysfunction Presenting as Autonomic Dysreflexia in a Patient with Spinal Cord Injury. Cureus (2017) 0.75
Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma (2004) 7.34
Autonomic dysreflexia. Spinal Cord (1999) 3.18
Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology (2004) 1.79
Autonomic dysreflexia in acute spinal cord injury: an under-recognized clinical entity. J Neurotrauma (2003) 1.63
Genetic manipulation of intraspinal plasticity after spinal cord injury alters the severity of autonomic dysreflexia. J Neurosci (2006) 1.30
Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem (2005) 1.30
Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain (2000) 1.20
A database of self-reported secondary medical problems among VA spinal cord injury patients: its role in clinical care and management. J Rehabil Res Dev (2002) 1.18
Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl (1997) 1.12
Telemetric blood pressure monitoring in conscious rats before and after compression injury of spinal cord. J Neurotrauma (2001) 1.10
Episodic hypertension due to autonomic dysreflexia in acute and chronic spinal cord-injured rats. Am J Physiol (1995) 1.02
Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord (1997) 0.98
Relationship between sympathetic activity and arterial pressure in conscious spinal rats. Am J Physiol (1997) 0.98
Changes in vesicular glutamate transporter 2, vesicular GABA transporter and vesicular acetylcholine transporter labeling of sacrocaudal motoneurons in the spastic rat. Exp Neurol (2005) 0.98
Rehabilitation in practice: Spasticity management. Clin Rehabil (2010) 0.95
Role of spinal NMDA and AMPA receptors in episodic hypertension in conscious spinal rats. Am J Physiol (1997) 0.93
Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord (1997) 0.87
Gabapentin. Pfizer. Curr Opin Investig Drugs (2002) 0.84
Gabapentin suppresses spasticity in the spinal cord-injured rat. Neuroscience (2007) 0.81
Depression in general practice: case thresholds and diagnosis. Br J Psychiatry (1985) 3.37
Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol (1987) 3.02
Decision-making in acute asthma. J R Coll Gen Pract (1983) 1.98
Epithelial overexpression of BDNF or NT4 disrupts targeting of taste neurons that innervate the anterior tongue. Dev Biol (2001) 1.13
Recovery of gastrointestinal tract motility and myoelectric activity change after abdominal surgery. Arch Surg (1997) 1.05
Vitamin D deficiency in adult British Hindu Asians: a family disorder. Br Med J (Clin Res Ed) (1985) 0.97
Chest radiography compared to laboratory markers in the detection of alcoholic liver disease. J R Coll Physicians Lond (1983) 0.96
Acetyl-L-carnitine treatment following spinal cord injury improves mitochondrial function correlated with remarkable tissue sparing and functional recovery. Neuroscience (2012) 0.95
Intraspinal sprouting of unmyelinated pelvic afferents after complete spinal cord injury is correlated with autonomic dysreflexia induced by visceral pain. Neuroscience (2008) 0.92
Targeting specific neuronal populations using adeno- and lentiviral vectors: applications for imaging and studies of cell function. Exp Physiol (2004) 0.91
Plasma corticotrophin-releasing factor (CRF) in abnormal pregnancy. Br J Obstet Gynaecol (1988) 0.91
High birth weight, asthma and atopy at the age of 16 yr. Pediatr Allergy Immunol (2008) 0.89
The relationship between disgust sensitivity, anxiety and obsessions. Behav Res Ther (2003) 0.89
Mycosis fungoides: an overview. J Surg Oncol (1983) 0.83
Oral absorption efficiency of acid-labile antibiotics from lipid-drug delivery systems. J Pharm Sci (1975) 0.76
Plasma corticotrophin-releasing factor (CRF) in normal pregnancy. Br J Obstet Gynaecol (1988) 0.76
Retinal pigment epithelial tear following intravitreal bevacizumab. Eye (Lond) (2006) 0.75
Synthesis and biological evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives. Org Biomol Chem (2013) 0.75
Human sparganosis. In northern United States. N Y State J Med (1978) 0.75
In vitro release of therapeutically active ingredients from polymer matrixes. J Pharm Sci (1976) 0.75